Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated “Moderate Buy” by Wall Street AnalystsDefense World · Oct 1, 2026
Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety ProfileGlobeNewsWire · Sep 21, 2026
Avalyn Appoints Robert J. Meyer, MD, to its Board of DirectorsGlobeNewsWire · Sep 16, 2026
Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewsWire · Sep 8, 2026
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary FibrosisGlobeNewsWire · Sep 8, 2026Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W.